The combination of Bayer's mineralocorticoid receptor antagonist (MRA) finerenone and Boehringer Ingelheim and Eli Lilly's ...

In another sign of recovery in digital health investing, Omada Health has priced an initial public offering (IPO) of $19 per ...

"Calquence plus venetoclax is the first and only all-oral combination treatment option with a second-generation BTK inhibitor ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

The tantalising development has been reported by researchers at the Peter Doherty Institute for Infection and Immunity in ...

Added to that, 23andMe suffered a massive data breach in 2023 that resulted in information from about 7 million people being ...

Zaynich is based on cefepime, a well-established beta-lactam antibiotic, combined with a novel beta-lactamase inhibitor ...

The award from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly ...

Uniting over 600 industry experts this September 22-25, the 15 th World Clinical Biomarkers & Companion Diagnostics (CDx) ...